Detalles de la búsqueda
1.
Patient-reported outcomes in the GARNET trial in patients with advanced or recurrent mismatch repair-deficient/microsatellite instability-high endometrial cancer treated with dostarlimab.
Int J Gynecol Cancer
; 2022 Aug 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-35973737
2.
Clinical activity and safety of the anti-PD-1 monoclonal antibody dostarlimab for patients with recurrent or advanced dMMR endometrial cancer.
Future Oncol
; 17(29): 3781-3785, 2021 Oct 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34427115
3.
Belantamab mafodotin in combination with novel agents in relapsed/refractory multiple myeloma: DREAMM-5 study design.
Future Oncol
; 17(16): 1987-2003, 2021 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-33682447
4.
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.
Lancet
; 387(10027): 1540-1550, 2016 Apr 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-26712084
5.
A phase II study of combined ridaforolimus and dalotuzumab compared with exemestane in patients with estrogen receptor-positive breast cancer.
Breast Cancer Res Treat
; 163(3): 535-544, 2017 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-28324268
6.
A randomized phase II trial of ridaforolimus, dalotuzumab, and exemestane compared with ridaforolimus and exemestane in patients with advanced breast cancer.
Breast Cancer Res Treat
; 165(3): 601-609, 2017 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-28681171
7.
Safety, antitumor activity, and pharmacokinetics of dostarlimab, an anti-PD-1, in patients with advanced solid tumors: a dose-escalation phase 1 trial.
Cancer Chemother Pharmacol
; 89(1): 93-103, 2022 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34750637
8.
Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET-a phase I, single-arm study.
J Immunother Cancer
; 10(1)2022 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35064011
9.
An Integrated Analysis of Dostarlimab Immunogenicity.
AAPS J
; 23(5): 96, 2021 07 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-34324079
10.
Clinical Activity and Safety of the Anti-Programmed Death 1 Monoclonal Antibody Dostarlimab for Patients With Recurrent or Advanced Mismatch Repair-Deficient Endometrial Cancer: A Nonrandomized Phase 1 Clinical Trial.
JAMA Oncol
; 6(11): 1766-1772, 2020 Nov 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33001143
11.
Clinical study of the novel cyclin-dependent kinase inhibitor dinaciclib in combination with rituximab in relapsed/refractory chronic lymphocytic leukemia patients.
Cancer Chemother Pharmacol
; 74(5): 1057-64, 2014 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-25217392
Resultados
1 -
11
de 11
1
Próxima >
>>